Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 700,000 ordinary shares of 25 pence each.
- Purchase Price: 1,436.48 pence per share.
- Treasury Holdings: 117,288,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,829,849,647 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company executed the purchase on September 27, 2005, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 700,000 share repurchase based on the disclosed price of 1,436.48 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the original shareholder authorization from the May 25, 2005 Annual General Meeting for remaining buyback capacity.